News
Backed by Yale Cancer Center Research, FDA Approves New Drug for Advanced Bladder Cancer
The U.S. Food and Drug Administration has granted accelerated approval to the drug enfortumab vedotin to treat adult patients with advanced urothelial or bladder cancer. The approval is the direct result of a multi-institutional clinical trial led by Yale Cancer Center and Smilow Cancer Hospital researchers.